Antihistamine shows promise for MS eye disorder in terminated trial
NCT ID NCT05338450
First seen May 11, 2026 · Last updated May 21, 2026 · Updated 5 times
Summary
This study tested whether clemastine fumarate, an allergy medicine, could improve eye movement in people with multiple sclerosis (MS) who have a specific eye condition called internuclear ophthalmoparesis. The trial planned to enroll 80 participants but was terminated early. Researchers measured eye movements using a special camera and also tested a single dose of fampridine to see if it could predict treatment response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Amsterdam UMC, location VUmc
Amsterdam, 1081 HV, Netherlands
Conditions
Explore the condition pages connected to this study.